Related Experiment Videos
COX 2-selective NSAIDs: biology, promises, and concerns
1Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, OH 44195, USA. mandelb@ccf.org
Cleveland Clinic Journal of Medicine
|May 20, 1999
Summary
Celecoxib, a selective cyclooxygenase 2 (COX 2) inhibitor, offers pain relief for osteoarthritis and rheumatoid arthritis with fewer gastrointestinal issues than traditional NSAIDs.
Area of Science:
- Pharmacology
- Drug development
- Gastroenterology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) carry risks of gastrointestinal ulceration and bleeding.
- Cyclooxygenase 2 (COX 2) selective inhibitors represent a novel therapeutic approach.
- Understanding the role of COX 1 and COX 2 inhibition is crucial for NSAID development.
Purpose of the Study:
- To review the pharmacology of celecoxib and other COX 2-selective NSAIDs.
- To discuss the potential clinical applications of these new drugs.
- To compare the efficacy and safety profiles of selective COX 2 inhibitors with traditional NSAIDs.
Main Methods:
- Review of clinical trial data.
- Pharmacological analysis of celecoxib's mechanism of action.
- Comparison of gastrointestinal safety profiles.
Main Results:
- Celecoxib demonstrates comparable efficacy to nonselective NSAIDs in treating osteoarthritis and rheumatoid arthritis.
- Selective COX 2 inhibition significantly reduces the incidence of gastrointestinal ulceration and bleeding.
- Clinical trials support the therapeutic potential of celecoxib.
Conclusions:
- Celecoxib offers a favorable risk-benefit profile for managing inflammatory pain conditions.
- COX 2-selective NSAIDs represent a significant advancement in pain management.
- Further research into the long-term clinical role of these agents is warranted.